A biomarker test to measure progression for Parkinson's Disease is available in the US before 2029
Gezondheid en geneeskundeOne-Off2jManifold MarketsGeen KYCGeverifieerde afwikkelingsgegevensRedelijk gekalibreerdHuidige gemeenschapsvoorspellingJa 71.7%
Voorspellers
6
Vraagtype
binary
Methodologie
Play-money forecasting platform
Brontype
Voorspelling
Marktdata
Bijgewerkt 16 uur geleden
Verouderd25 apr 23, 16:13 UTC2 jan 29, 06:59 UTC
Trends
Regels
There will be a test of a biomarker which meaningfully correlates with parkinson's progression for at least a signficant subset (>10% of those diagnosed clinically) of people with Parkinson's disease in the US before 2029
- examples: Patient has classic non-genetic PD from a clinical diagnosis based on symptoms (rigidity, etc.).
- There will be a test which they can take which shows the severity of the disease, and which when given repeatedly can be used to measure how much or less the disease has progressed
